Cancer Research UK DNA Repair Enzymes Group, Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer, United Kingdom; Bioinformatics Lab, School of Life Sciences, University of Sussex, Falmer, United Kingdom
Yusuf I Ali
Bioinformatics Lab, School of Life Sciences, University of Sussex, Falmer, United Kingdom; Sussex Drug Discovery Centre, School of Life Sciences, University of Sussex, Falmer, United Kingdom
Charlotte EL Fisher
Cancer Research UK DNA Repair Enzymes Group, Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer, United Kingdom
Sussex Drug Discovery Centre, School of Life Sciences, University of Sussex, Falmer, United Kingdom; Medicines Discovery Institute, Park Place, Cardiff University, Cardiff, United Kingdom
BLM (Bloom syndrome protein) is a RECQ-family helicase involved in the dissolution of complex DNA structures and repair intermediates. Synthetic lethality analysis implicates BLM as a promising target in a range of cancers with defects in the DNA damage response; however, selective small molecule inhibitors of defined mechanism are currently lacking. Here, we identify and characterise a specific inhibitor of BLM’s ATPase-coupled DNA helicase activity, by allosteric trapping of a DNA-bound translocation intermediate. Crystallographic structures of BLM-DNA-ADP-inhibitor complexes identify a hitherto unknown interdomain interface, whose opening and closing are integral to translocation of ssDNA, and which provides a highly selective pocket for drug discovery. Comparison with structures of other RECQ helicases provides a model for branch migration of Holliday junctions by BLM.